Cytori Therapeutics Inc.Find Ratings Reports
CYTORI THERAPEUTICS INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. CYTORI THERAPEUTICS INC has weak liquidity. Currently, the Quick Ratio is 0.57 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has increased by 18.33% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||1.53||3.03|
|Net Income ($mil)||-4.29||-4.92|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||10.23||12.91|
|Total Assets ($mil)||31.62||34.61|
|Total Debt ($mil)||13.62||17.64|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||41.16||32.04|
|Return on Assets||-71.75||-63.7|
|Return on Equity||-205.1||-200.67|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||5.78||2.17|
|Div / share||0.0||0.0|
|Book value / share||2.25||5.06|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||366642.0||1646438.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 0.93 indicates a significant discount versus the S&P 500 average of 3.29 and a significant discount versus the industry average of 14.33. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. After reviewing these and other key valuation criteria, CYTORI THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|CYTX NM||Peers 40.64||CYTX NM||Peers 50.79|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CYTX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CYTX's P/CF is negative making the measure meaningless.
|CYTX NA||Peers 30.43||CYTX NA||Peers 0.39|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CYTX 0.93||Peers 14.33||CYTX 37.69||Peers 27.58|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CYTX is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
CYTX is expected to have an earnings growth rate that significantly exceeds its peers.
|CYTX 1.88||Peers 72.30||CYTX -43.67||Peers 339.57|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CYTX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CYTX significantly trails its peers on the basis of sales growth